undamentalytics Newsletter
Sign in

Ginkgo Bioworks Holdings, Inc. balance sheet

At the end of fiscal 2025, Ginkgo Bioworks Holdings, Inc. had total assets of $1.12bn, total liabilities of $611m and shareholders' equity of $509m. It held $167m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents4953811,5501,31694456216785
Receivables—171328117222413
Inventory—3340———
Total current assets—4271,7231,4501,002603472333
Goodwill222160490——
Total assets—6752,0712,5391,6651,3771,120990
Accounts payable—148109141110
Deferred revenue (current)—29334844281913
Total current liabilities—731351731641079673
Total debt00000000
Total liabilities—205504803568661611570
Shareholders' equity5024611,5051,7361,097716509420
Non-controlling interests and other (assets − liabilities − equity)——62—————
Shares outstanding————50m54m58m64m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: DNA vs SPRYDNA vs RCUSDNA vs XNCR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ginkgo Bioworks Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ginkgo Bioworks Holdings, Inc.